CytomX Therapeutics
CTMX
70 hedge funds and large institutions have $48.1M invested in CytomX Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 10 closing their positions.
620% more call options, than puts
Call options by funds: $36K | Put options by funds: $5K
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
1% more funds holding
Funds holding: 69 → 70 (+1)
5.84% less ownership
Funds ownership: 65.53% → 59.69% (-5.8%)
20% less capital invested
Capital invested by funds: $60.4M → $48.1M (-$12.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.85M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$950K |
| 3 |
JP Morgan Chase
New York
|
+$873K |
| 4 |
Millennium Management
New York
|
+$711K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$473K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$5.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.54M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.12M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$816K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$538K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Invesco
Atlanta,
Georgia
| – | -$44.2K | -37,464 | Closed |
|
77
Goldman Sachs
New York
| – | -$14.2K | -12,000 | Closed |
|
|
EWA
78
EP Wealth Advisors
Torrance,
California
| – | -$12.3K | -10,432 | Closed |
|
79
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$138 | -117 | Closed |
|
80
Simplex Trading
Chicago,
Illinois
| – | +$545 | +507 | New |
|
CTMX Hedge Fund Activity: Q4 2024 in Review
70 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2024, worth a combined $48.1M — down 20% from $60.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CTMX positions and 10 closed out — a net gain of 2 holders — while 24 added to existing stakes and 21 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.85M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $5.7M sold.
- 70 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2024, up from 69 in Q3 2024.
- Funds reported $48.1M of CytomX Therapeutics stock for Q4 2024, down 20% quarter-over-quarter.
- 12 funds opened new CytomX Therapeutics positions in Q4 2024 and 10 closed out, a net change of +2 holders.
- The largest CytomX Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $2.85M added.
- The largest CytomX Therapeutics seller in Q4 2024 was Janus Henderson Group, an estimated $5.7M sold.
Based on aggregated 13F filings for Q4 2024.